|Blanckaert, Peter||22/03/2018 13:43||Blanckaert, Peter||12/01/2018 15:57|
|Blanckaert, Peter||06/12/2017 23:20||Blanckaert, Peter||06/12/2017 23:12|
|Blanckaert, Peter||12/07/2017 12:21||Blanckaert, Peter||12/07/2017 12:07|
|Blanckaert, Peter||12/07/2017 12:11||Blanckaert, Peter||12/07/2017 12:08|
|Blanckaert, Peter||12/07/2017 12:00||Blanckaert, Peter||12/07/2017 11:52|
|Blanckaert, Peter||12/07/2017 11:26||Blanckaert, Peter||18/05/2017 10:28|
|Blanckaert, Peter||03/04/2017 10:38||Blanckaert, Peter||29/03/2017 17:24|
|Antoine, Jerome||16/12/2016 08:03||Antoine, Jerome||27/10/2016 09:06|
|Blanckaert, Peter||14/12/2016 12:36||Blanckaert, Peter||14/12/2016 12:05|
|Antoine, Jerome||27/10/2016 09:05||Antoine, Jerome||29/09/2016 10:47|
On 12 January 2018 the Dutch National Focal Point reported to the
EMCDDA that in the last week, atropine has been detected in samples of
cocaine and ketamine from North Brabant, Netherlands. In addition, they
reported that poisonings suspected to involve atropine have been
reported earlier this month in North Brabant and the Rotterdam region
In addition to these reports, the Belgian National Focal Point
also reported today that there has been at least three cases in the past
week in the Antwerp region of Belgium where atropine was detected in the
urine of known cocaine users. The Focal Point reported that atropine has
not yet been detected in powder samples in Belgium.
Symptoms of atropine poisoning include: amnesia, disorientation, visual
hallucinations, ataxia, psychosis, coma, tachycardia, mydriasis,
restlessness, urinary retention, disturbed speech and swallowing .
Atropine poisoning can be fatal due to respiratory depression and
The purpose of this communication is to:
inform you of
these recent detections of atropine in cocaine and ketamine samples
in the Netherlands;
suspected poisonings and detections in urine samples have also been
there is a potential for severe toxicity with atropine;
request that you report any recent detections of atropine as
soon as possible to the Belgian Early Warning System drugs using
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) just released the report on the formal risk assessment for furanylfentanyl.
This publication presents the data and findings of the risk assessment on N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide (furanylfentanyl),
carried out by the extended Scientific Committee of the EMCDDA on 23 May 2017.
On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 15 November 2017,
the Council decided that furanylfentanyl should be subject to control measures across the Member States.
The entire risk assessment report can be downloaded in pdf format
The U.S. Drug Enforcement Administration has issued the following notice of intent:
2017 European Drug
Report was launched at the beginning of June.
The report provides an overview of the
drug situation in Europe, for every single country.
This was accompanied for the first time by 30 Country Drug Reports,
presenting summaries of national drug phenomena (EU 28, Turkey and Norway).
The EMCDDA has released its report on high-risk drug use and new psychoactive substances (NPS).
This report provides a first look at the emergence of more problematic forms of use of new psychoactive substances among a range of demographic groups,
including opioid and amphetamine injectors, prisoners, the homeless and men who have sex with men.
It explores, in particular, the use of synthetic cathinones, synthetic cannabinoids and new synthetic opioids, as well as related harms and responses.
At their recently concluded meeting in Vienna, the Commission on Narcotic Drugs, an organization under the United Nations, has decided to place ten Novel Psychoactive Substances under international control.
More information can be found here. The substances are:
· U-47700 - Schedule I
· Butyrfentanyl- Schedule I
· 4-Methylethcathinone (4-MEC) - Schedule II
· Ethylone - Schedule II
· Pentedrone (α-Methylaminovalerophenone) - Schedule II
· Ethylphenidate (EPH) - Schedule II
· Methiopropamine (MPA) - Schedule II
· MDMB-CHMICA - Schedule II
· 5F-APINACA (5F-AKB-48) - Schedule II
· XLR-11 - Schedule II
March 1, 2017 - A New Psychoactive Substances Act entered into force in Germany on 26 November 2016, controlling specific new psychoactive substances (NPS).
Under the new act, NPS are defined as any substance or preparation belonging to the specified generic (group) definitions for synthetic cannabinoids and compounds derived from 2-phenylethylamine.
The new act prohibits producing, trading, importing, offering and possessing NPS and empowers police and customs services to confiscate substances using their general powers to protect life and health.
The text can be found here.
March 1, 2017 - The EU reacted to serious concerns over the use of the synthetic cannabinoid MDMB-CHMICA by deciding to subject it to ‘control measures’ on February 27th, 2017.
The substance in question has been raising health concerns in Europe after harmful effects related to its use were reported by the Member States through the EU Early Warning System, coordinated by the EMCDDA.
Consumption of DMB-CHMICA resulted in dozens of deaths and intoxications throughout Europe during the summer of 2015.
During the risk assessment, which was held in July 2016, the EMCDDA scientific committee concluded that the potency of MDMB-CHMICA and the highly variable amounts of the compound encountered in herbal products constitute a serious risk of acute toxicity.
The risk assessment full text can be found on the website of the EU Council.
Welcome to your site!
Add a new image, change this welcome text or add new lists to this page by clicking the edit button above. You can click on Shared Documents to add files or on the calendar to create new team events. Use the links in the getting started section to share your site and customize its look.